SIETES :: 92751 citas

Resultados de la búsqueda por NÁUSEAS REFINAR BÚSQUEDA

1.

Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]

2.

Freeman TP, Hindocha C, Green SF, Bloomfield MAP. Medicinal use of cannabis based products and cannabinoids. BMJ 2019;365:4 de abril. [Ref.ID 103086]

3.

Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 2018;18:febrero. [Ref.ID 102909]

4.

Robertson K, Marshman LAG, Plummer D, Downs E. Effect of gabapentin vs pregabalin on pain intensity in adults ith chronic sciatica: a randomized clinical trial. JAMA Neurology 2018:15 de octubre. [Ref.ID 102863]

5.

Silverman E. A drug maker paid Kim Kardashian $500,000 for a few social media posts. Were they worth it?. STAT Daily Recap 2018:2. [Ref.ID 102707]

6.

Anónimo. Nétupitant + palonosétron et prévention des vomissements chimio-induits. Prescrire 2018;38:176-7. [Ref.ID 102587]

7.

Casassus B. Risks of reformulation: French patients complain after Merck modifies levothyroxine pills. BMJ 2018;360:k714. [Ref.ID 102544]

8.

Patel P, Leeder JS, Piquette-Miller M, Dupuis LL. Aprepitant and fosaprepitant drug interactions: a systematic review. Br J Clin Pharmacol 2017;83:2148-62. [Ref.ID 102081]

9.

Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]

10.

Bradford AC, Bradford WD. Medical marijuana laws may be associated with a decline in the number of prescriptions for Medicaid enrollees. Health Affairs 2017;36:1 de mayo. [Ref.ID 101570]

11.

DREAMS Trial Collaborators and West Midlands Research Collaborative. Dexamethasone versus standard treatment for postoperative nausea and vomiting in gastrointestinal surgery: randomised controlled trial (DREAMS Trial). BMJ 2017;357:j1455. [Ref.ID 101540]

12.

Anónimo. FDA approves drug for pregnancy-related nausea and vomiting. DIA Daily 2016:2. [Ref.ID 100938]

13.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Lafky JM, Loprinzi CL. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016;375:134-42. [Ref.ID 100630]

14.

Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]

15.

Anónimo. FDA approves first dronabinol solution for oral use. FDA U.S. Food and Drug Administration 2016:2. [Ref.ID 100472]

16.

Pasina L, Zanotta D, Puricelli S, Bonoldi G. Acute neurological symptoms secondary to hypomagnesemia induced by proton pump inhibitors: a case series. Eur J Clin Pharmacol 2016;72:641-3. [Ref.ID 100252]

17.

Carstairs S. Ondansetron use in pregnancy and birth defects: A systematic review. Obstet Gynecol 2016;127:878-83. [Ref.ID 100204]

18.

Jaspers L, Feys F, Franco OH, Leusink P, Laan ETM. Efficacy and safety of flibanserin for the treatment of hypoactive sexual desire disorder in women. A systematic review and meta-analysis. JAMA Intern Med 2016;176:453-62. [Ref.ID 100072]

19.

Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]

20.

Voelker R. New pancreatic cancer drug. JAMA 2015;314:2227. [Ref.ID 99728]